Follow
Anthony D'Ippolito
Anthony D'Ippolito
Verified email at duke.edu
Title
Cited by
Cited by
Year
Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers
IB Hilton, AM D'ippolito, CM Vockley, PI Thakore, GE Crawford, TE Reddy, ...
Nature biotechnology 33 (5), 510-517, 2015
19802015
Expanded encyclopaedias of DNA elements in the human and mouse genomes
JE Moore, MJ Purcaro, HE Pratt, CB Epstein, N Shoresh, J Adrian, T Kawli, ...
Nature 583 (7818), 699-710, 2020
10752020
Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements
PI Thakore, AM D'ippolito, L Song, A Safi, NK Shivakumar, AM Kabadi, ...
Nature methods 12 (12), 1143-1149, 2015
9542015
Targeted epigenetic remodeling of endogenous loci by CRISPR/Cas9-based transcriptional activators directly converts fibroblasts to neuronal cells
JB Black, AF Adler, HG Wang, AM D’Ippolito, HA Hutchinson, TE Reddy, ...
Cell stem cell 19 (3), 406-414, 2016
2292016
Direct GR binding sites potentiate clusters of TF binding across the human genome
CM Vockley, AM D’Ippolito, IC McDowell, WH Majoros, A Safi, L Song, ...
Cell 166 (5), 1269-1281. e19, 2016
1852016
Glucocorticoid receptor recruits to enhancers and drives activation by motif-directed binding
IC McDowell, A Barrera, AM D'Ippolito, CM Vockley, LK Hong, ...
Genome research 28 (9), 1272-1284, 2018
1042018
Pre-established chromatin interactions mediate the genomic response to glucocorticoids
AM D'Ippolito, IC McDowell, A Barrera, LK Hong, SM Leichter, LC Bartelt, ...
Cell systems 7 (2), 146-160. e7, 2018
952018
Phosphatidylinositol 3-kinase (PI3K) signaling via glycogen synthase kinase-3 (Gsk-3) regulates DNA methylation of imprinted loci
AP Popkie, LC Zeidner, AM Albrecht, A D'Ippolito, S Eckardt, DE Newsom, ...
Journal of Biological Chemistry 285 (53), 41337-41347, 2010
952010
Perspectives on ENCODE
MP Snyder, TR Gingeras, JE Moore, Z Weng, MB Gerstein, B Ren, ...
Nature 583 (7818), 693-698, 2020
872020
Epidemiology of pediatric holiday-related injuries presenting to US emergency departments
A D'Ippolito, CL Collins, RD Comstock
Pediatrics 125 (5), 931-937, 2010
472010
Human genome-wide measurement of drug-responsive regulatory activity
GD Johnson, A Barrera, IC McDowell, AM D’Ippolito, WH Majoros, ...
Nature communications 9 (1), 5317, 2018
402018
Perspectives on ENCODE
F Abascal, R Acosta, NJ Addleman, J Adrian, V Afzal, B Aken, JA Akiyama
Nature 583 (7818), 693-699, 2020
192020
Genomic signatures of high-altitude adaptation and chromosomal polymorphism in geladas
KL Chiou, MC Janiak, IA Schneider-Crease, S Sen, F Ayele, IS Chuma, ...
Nature ecology & evolution 6 (5), 630-643, 2022
172022
A long-range flexible billboard model of gene activation
CM Vockley, IC McDowell, AM D'Ippolito, TE Reddy
Transcription 8 (4), 261-267, 2017
162017
Gene expression profiling in mouse embryonic stem cells reveals glycogen synthase kinase-3-dependent targets of phosphatidylinositol 3-kinase and Wnt/β-catenin signaling pathways
CM Bartman, J Egelston, S Kattula, LC Zeidner, A D’Ippolito, BW Doble, ...
Frontiers in Endocrinology, 133, 2014
162014
Glycogen synthase kinase-3 (Gsk-3) plays a fundamental role in maintaining DNA methylation at imprinted loci in mouse embryonic stem cells
GD Meredith, A D'Ippolito, M Dudas, LC Zeidner, L Hostetter, K Faulds, ...
Molecular Biology of the Cell 26 (11), 2139-2150, 2015
102015
Abstract C091: Preclinical evaluation of PK, PD, and antitumor activity of the oral, non-covalent, potent and highly selective CDK7 inhibitor, SY-5609, provides rationale for …
LH Johannessen, S Hu, N Ke, A D'Ippolito, N Rajagopal, J Marineau, ...
Molecular Cancer Therapeutics 18 (12_Supplement), C091-C091, 2019
92019
From prescription to transcription: Genome sequence as drug target
C Guo, AM D’Ippolito, TE Reddy
Cell 162 (1), 16-17, 2015
82015
518MO Tolerability and preliminary clinical activity of SY-5609, a highly potent and selective oral CDK7 inhibitor, in patients with advanced solid tumors
M Sharma, B Bashir, E Hamilton, D Juric, K Papadopoulos, D Richardson, ...
Annals of Oncology 32, S587-S588, 2021
62021
Activity of SY-5609, an oral, noncovalent, potent, and selective CDK7 inhibitor, in preclinical models of colorectal cancer.
L Johannessen, N Ke, P Sawant, W Dworakowski, A D'Ippolito, S Hu, ...
Journal of Clinical Oncology 38 (15_suppl), 3585-3585, 2020
42020
The system can't perform the operation now. Try again later.
Articles 1–20